Summary: Research into psychedelic medications shows that psychedelics help mental health for some people with some disorders under some protocols in some treatment situations, but as of 2026 – despite significant media attention – research does not confirm that psychedelics have revolutionized mental health treatment.
Key Points:
- No psychedelic medication is FDA-approved for human use.
- One non-psychedelic medication with psychedelic properties, Spravato®, has been approved for mental health disorders like treatment-resistant depression (TRD), major depressive disorder (MDD), and MDD with suicidal thoughts.
- Ketamine, another non-psychedelic medication with psychedelic properties, is used off-label for treatment-resistant depression and other mental health disorders but has not been approved by the FDA for mental health treatment.
- Members of the general public should always defer to medical professionals when considering any medication, and remember headlines sensationalize content to get clicks.
NOTE: DO NOT TAKE AN ILLICIT PSYCHEDELIC FOR YOUR MENTAL HEALTH.
IN THE U.S. IN 2026 ALL PSYCHEDELICS ARE SCHEDULE III CONTROLLED SUBSTANCES.
UNLESS YOU’RE IN AN APPROVED AND REGULATED CLINCAL TRIAL, TAKING PSYCHEDELICS IS BOTH RISKY AND ILLEGAL.
Looking for New Medications for Mental Health: How Do Regular People Know What’s What?
Over the past decade, awareness about mental health disorders and mental health treatment has increased dramatically. This development follows increases in suicidality and rates of suicide among teens and young adults between 2010 and 2020, increases in anxiety and depression associated with the coronavirus pandemic and a highly charged social environment from 2020 to the present, and a two-decade long drug overdose crisis that’s only recently shifted direction.
Scientists and mental health researchers work to find new treatments for mental health disorders such as anxiety, depression, posttraumatic stress disorder, and obsessive-compulsive disorder every day. They publish results in peer-reviewed medical journals, whose editors and staff may in turn write and share press releases about important or promising new treatments for disorders.
Online media outlets pick up these press releases, and in some cases, generate sensational headlines like this:
Just One Dose of Psilocybin Reduces Depressive Symptoms
Study Shows Exercise as Good As Antidepressants for Major Depressive Disorder
One Session With Ibogaine Cured Chronic PTSD in a Combat Veteran
We made those headlines up because we don’t want to deter specific websites/services for sharing information about mental health. We’re glad they are, and believe the presence of media outlets that offer quick, easy-to-read reports about developments in mental health treatment are a good thing, overall.
But we need to remind general readers that on one level, these quick-hit stories function to get clicks to get eyes on the page to increase ad revenue. That’s the nature of our online world. To determine whether psychedelics get more press, and better press, than standard mental health medications such as antidepressants, a group of researchers conducted a study called “Media Hype Regarding Psychedelic Treatments for Depression and PTSD From 2017 To 2024” with the following goal:
“To measure potential hype, we conducted analyses comparing media coverage of psychedelics to FDA-approved antidepressants for major depressive disorder and posttraumatic stress disorder.”
Let’s take a look at what they found.
Help or Hype? Psychedelics in the News
To determine whether psychedelics get elevated press coverage that qualifies as hype, researchers used natural language processing, an LLM/AI tool, and a press database to examine the sentiment and content related to psychedelics and antidepressants in 6,805 separate publications in stories released between 2017 and 2024.
Between 2017 and 2024:
- Positive emotions appeared more often in reference to psychedelics than antidepressants.
- Positive overall sentiments appeared more often in reference to psychedelics than antidepressants.
- Negative emotion appeared more often in reference to antidepressants than psychedelics.
- Risk language appeared more often in reference to antidepressants than psychedelics.
The data showed two unexpected findings in the opposite direction. First, language referring to reward appeared strongly associated with antidepressants, while language expressing negative sentiment appeared strongly associated with psychedelics.
However, those two contrary results didn’t match the weight of results praising psychedelics and criticizing antidepressants. Here’s the takeaway from the research the study authors highlighted:
“Overall, results suggest that media coverage emphasizes the purported benefits of psychedelics and drawbacks of established medications, which may impact patient expectations, adherence with treatment, and patient outcomes.”
We’ll discuss these results briefly, below.
Open to New Ideas, But Follow the Evidence
In our work with patients with serious mental health challenges and clinical mental health disorders, we combine the best traditional practices with the best innovative, leading-edge treatments. Every technique, medication, or complementary approach we use has support from data in clinical studies published by peer-reviewed medical journals.
Evidence does show that for some patients, with some disorders, under some protocols, psychedelic medications help mental health. However, that help and symptom relief has occurred in strictly controlled clinical studies, with patients under medical supervision in case of emergency. More importantly, not every study reports positive outcomes or significant symptom relief.
Yes, the results are promising and offer hope for improved treatment outcomes in the future. And in some cases, for some disorders, under some protocols, research shows real potential for psychedelics and the future of psychedelic psychotherapy.
When patients ask us about a news story they read about a psychedelic revolution for depression treatment, we advise patience, perspective, and caution. Everything we know about mental health disorders indicates that effective treatment involves integrated, holistic, and comprehensive treatment plans. Effective treatment needs to address not only symptoms and symptom relief but also support and promote effective functioning in all areas of life, including family, school, work, and relationships.
What we need to counter is the idea that we may discover a magic pill, i.e. a psychedelic medication, that will somehow fix depression, anxiety, or PTSD, just by taking it.
Mental health is part of total health. Total health is about more than symptom relief. It’s about helping patients live and thrive on all levels. While psychedelics may offer relief in some treatment contexts now, and may improve in the future, the work of mental health recovery – currently – involves engaging in therapy, using medication when needed, and making the positive and proactive lifestyle choices that promote total health.
Where psychedelics are concerned, we encourage people to believe in the hope. But please, don’t buy into hype that sounds too good to be true.
Gianna Melendez
Jodie Dahl, CpHT